<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04118556</url>
  </required_header>
  <id_info>
    <org_study_id>DSC-BROMS-1</org_study_id>
    <secondary_id>2019-002186-36</secondary_id>
    <nct_id>NCT04118556</nct_id>
  </id_info>
  <brief_title>Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT</brief_title>
  <acronym>2017-00355</acronym>
  <official_title>A Multicenter, Open-label, Randomized, Phase I/II Clinical Trial Comparing Safety and Durable Overall Response Day 56 in Patients With Steroid Resistent Acute GvHD After Allogeneic Hematopoietic Stem Cell Transplant Treated With DSC or BAT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mats Remberger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Swedish Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A two-stage design. An open, non-randomized, 3+3 dose escalating scheme will be used in the&#xD;
      first stage of the study. A randomized (1:1) phase II open label study of DSC compared to&#xD;
      Investigator choice Best Available Therapy (BAT) in allogeneic hematopoietic stem cell&#xD;
      transplant recipients with Grades II-IV steroid refractory acute graft vs. host disease in&#xD;
      the second part of the study. Patients in each phase will receive 2 doses of DSC. In the&#xD;
      second part (Phase II) additional doses (up to 6 doses) may be given depending on response.&#xD;
&#xD;
      No cross-over are planned in the second stage of the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main inclusion criteria:&#xD;
&#xD;
      Adult patients (age â‰¥ 18 years) with steroid refractory (SR) acute GvHD (aGVHD) grades II-IV&#xD;
      after allo-HSCT.&#xD;
&#xD;
      Signed written study informed consent once SR-aGvHD is confirmed.&#xD;
&#xD;
      Main exclusion criteria:&#xD;
&#xD;
      Presence of an active uncontrolled infection requiring treatment. Has received systemic&#xD;
      treatment for aGvHD apart from steroids. Clinical presentation resembling de novo chronic&#xD;
      GvHD or GvHD overlap syndrome. Known human immunodeficiency virus infection (HIV). Patients&#xD;
      suffering on active tuberculosis or viral hepatitis. Significant respiratory disease Presence&#xD;
      of severely impaired renal function Patients with coagulopathy Pregnant or nursing&#xD;
      (lactating) women Malignancy that has required treatment in the previous two years Any&#xD;
      condition that would, in the Investigator's judgment, interfere with full participation in&#xD;
      the study.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      This is a phase I/II, multicenter, open-label trial of DSC in patients with steroid&#xD;
      refractory acute GvHD grades II-IV.&#xD;
&#xD;
      The trial will consist of 2 main parts: Phase 1 (open, non-randomized, 3+3 DSC dose&#xD;
      escalating scheme), and Phase II, randomized (1:1), open label study investigating the&#xD;
      efficacy and safety of DSC vs. BAT added to the patient's immunosuppressive regimen in adults&#xD;
      with SR-aGvHD.&#xD;
&#xD;
      Phase I dose escalating study. The main objective of the first part of the study is safety&#xD;
      and tolerability of two different doses of DSC and to establish the optimal dose for the&#xD;
      second, Phase II, part of the study. Six patients will be enrolled, 3 patients given the&#xD;
      lower dose (1x10^6 DSC/kg) and 3 patients given the higher dose (3x10^6 DSC/kg). Patients&#xD;
      will receive 2 doses of DSC (low or high) one week apart. If none of the initial 3 patients&#xD;
      in the low-dose cohort experience a Severe Adverse Event (SAE), enrolment into the high dose&#xD;
      level will commence. If the low and high dose in the Phase I study show similar safety&#xD;
      results, the lower dose will be chosen for the Phase II, randomized study. The reason for the&#xD;
      chosen doses in the phase I part is that in the pilot study, 1x10^6/kg showed very promising&#xD;
      clinical results without any significant side-effects. The higher dose is chosen as this is&#xD;
      the highest dose used clinically without any severe side-effects.&#xD;
&#xD;
      The dose proposed for cohort 2 may change pending review of the data from the previous cohort&#xD;
      by the Safety committee.&#xD;
&#xD;
      In the second part of the study (Phase II) primary objectives will be safety and to compare&#xD;
      durable overall response (DOR) at 56 days after randomization between patients receiving DSC&#xD;
      with patients receiving BAT as treatment for SR acute GvHD grades II-IV. Target enrollment is&#xD;
      50 patients, 25 in the DSC treatment-arm and 25 in the BAT arm. Patients will be given the&#xD;
      optimal dose of DSC from the Phase I, dose escalating part of the study, as mentioned above.&#xD;
      At least 2 doses of DSC will be given one week apart. Additional doses of DSC (maximum 6&#xD;
      doses) may be given depending on response. Additional doses (beyond the first 2 doses) may be&#xD;
      given one week apart until response, or whenever needed if aGVHD flare occur within 6 months&#xD;
      after randomization (EOT).&#xD;
&#xD;
      BAT: Investigator's choice Best Available Therapy (BAT) will vary depending upon&#xD;
      Investigator's choice identified prior to randomization. Dose and frequency will depend on&#xD;
      label (where approved) and institutional guidelines for various BAT.&#xD;
&#xD;
      Primary objective&#xD;
&#xD;
      In the phase I part:&#xD;
&#xD;
        -  Assess the safety and tolerability profile of DSC&#xD;
&#xD;
        -  Select the recommended DSC dose for the phase II study.&#xD;
&#xD;
      In the phase II part:&#xD;
&#xD;
        -  Assess the Safety of DSC.&#xD;
&#xD;
        -  Durable Overall Response (DOR) at Day 56.&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
        -  To assess Overall Response Rate (ORR) at day 28&#xD;
&#xD;
        -  To assess 1-year Overall Survival (OS)&#xD;
&#xD;
        -  To assess 1-year Non-Relapse Mortality (NRM)&#xD;
&#xD;
        -  To assess incidence of infections&#xD;
&#xD;
      Exploratory objectives&#xD;
&#xD;
        -  To assess the cumulative steroid dose until Day 56 and Day 90&#xD;
&#xD;
        -  To assess Event-Free Survival (EFS)&#xD;
&#xD;
        -  To assess incidence of Malignancy Relapse/Progression&#xD;
&#xD;
        -  To measure the incidence of chronic GvHD&#xD;
&#xD;
        -  To measure immune reconstitution&#xD;
&#xD;
        -  To evaluate changes in Patient Reported Outcomes&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A two-stage design. An open, non-randomized, 3+3 dose escalating scheme will be used in the first stage of the study. A randomized (1:1) phase II open label study of DSC compared to Investigator choice Best Available Therapy (BAT) in allogeneic hematopoietic stem cell transplant recipients with Grades II-IV steroid refractory acute graft vs. host disease in the second part of the study. Patients in each phase will receive 2 doses of DSC. In the second part (Phase II) additional doses (up to 6 doses) may be given depending on response.&#xD;
No cross-over are planned in the second stage of the study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability evaluation including Severe Adverse Events (SAE).</measure>
    <time_frame>5 years</time_frame>
    <description>Adverse events will be assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Durable Response to treatment</measure>
    <time_frame>56 days</time_frame>
    <description>Durable Overall Response (DOR) day 56.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with overall response (CR+PR) at day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Overall Response Rate (ORR) at day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Death within 1 year after inclusion in study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Non-Relapse Mortality (NRM)</measure>
    <time_frame>1 year</time_frame>
    <description>Death of any cause with enduring complete remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections</measure>
    <time_frame>1 year</time_frame>
    <description>Serious infections occurring after inclusion in study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Quality of Life</measure>
    <time_frame>1 year</time_frame>
    <description>Change of self-experienced well-being (Quality of Life)(FACT-BMT version 4) at four time-points after inclusion. Scoring procedures consist of summing the items with reversed scoring (0-4p where 0=best and 4=worst) for several items which produces individual subscale scores (0-24/28p) and an overall score (0-200p).&#xD;
The FACT-BMT (Functional Assessment of Cancer Therapy-Bone Marrow Transplant) has a total of 50 questions. This is a questionnaire of general questions divided into four primary quality of life domains: physical well-being (PWB; 7-items), social/family well-being (SWB; 7-items), emotional well-being (EWB; 6-items); and functional well-being (FWB; 7-items), 18 items address the BMT related side effects, specifically designed to assess the BMT patients' quality of life. Five other questions from different QoL questionnaire were added as they were considered relevant to FACT-BMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Relapse</measure>
    <time_frame>5 year</time_frame>
    <description>Recurrence of the disease the patient were transplanted for.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of secondary malignancies</measure>
    <time_frame>5 year</time_frame>
    <description>Occurrence of other malignancies than the patient were transplanted for.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD</measure>
    <time_frame>5 year</time_frame>
    <description>Occurrence of chronic GVHD.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>GVHD, Acute</condition>
  <arm_group>
    <arm_group_label>Decidua Stroma Cells (DSC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placenta derived decidua stroma cells (DSC). In the first phase I part, two different dose levels will be used, 1x10^6/kg and 3x10^6/kg. Two doses, one week apart, will be given. The decision to proceed to the next dose level will depend on results observed at the previous dose level.&#xD;
The dose in the randomized part will be based on the findings in the phase I part. In the Phase II study all patients will receive 2 doses, one week apart. Depending on response, up to 6 doses in total may be given. Additional doses (beyond the first 2 doses) may be given one week apart until response.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best Available Treatment (BAT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Decidua Stroma Cells (DSC)</intervention_name>
    <description>Placenta-derived Decidua Stroma Cells. The product consists of a viable allogeneic DSCs frozen in 5% of human serum albumin (HSA) in sodium chloride (NaCl) 0.9% and 10% dimethylsulfoxide (DMSO), that is thawed and immediately diluted in 40 mL sodium chloride (NaCl) 0.9% prior to infusion. That will give a final concentration of 2.2% HSA and 2% DMSO.&#xD;
DSC will be infused when steroid-refractory acute GVHD after allogenic stem-cell transplantation has been diagnosed. Two doses, one week apart, will be given to all patients. Additional doses will be used depending on response.</description>
    <arm_group_label>Decidua Stroma Cells (DSC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Best available Treatment (BAT)</intervention_name>
    <description>The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.</description>
    <arm_group_label>Best Available Treatment (BAT)</arm_group_label>
    <other_name>ECP, Everolimus, Sirolimus, Etanercept, Vedolizumab, Ruxolitinib, Infliximab.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patients (age â‰¥ 18 years) with steroid refractory acute GvHD grades II-IV after&#xD;
             allo-HSCT.&#xD;
&#xD;
          2. Signed written study informed consent once SR-aGvHD is confirmed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of an active uncontrolled infection including significant bacterial, fungal,&#xD;
             viral or parasitic infection requiring treatment.&#xD;
&#xD;
          2. Has received systemic treatment for aGvHD apart from steroids.&#xD;
&#xD;
          3. Clinical presentation resembling de novo chronic GvHD or GvHD overlap syndrome.&#xD;
&#xD;
          4. Pregnant or lactating women.&#xD;
&#xD;
          5. Significant respiratory disease.&#xD;
&#xD;
          6. Presence of severely impaired renal function&#xD;
&#xD;
          7. Any corticosteroid therapy for indications other than aGvHD&#xD;
&#xD;
          8. Previous participation in a study of any investigational treatment agent within 30&#xD;
             days&#xD;
&#xD;
          9. Known human immunodeficiency virus infection (HIV).&#xD;
&#xD;
         10. Patients suffering on active tuberculosis or viral hepatitis&#xD;
&#xD;
         11. Significant respiratory disease&#xD;
&#xD;
         12. Presence of severely impaired renal or liver function&#xD;
&#xD;
         13. History of progressive multifocal leuko-encephalopathy&#xD;
&#xD;
         14. Patients with coagulopathy&#xD;
&#xD;
         15. History of severe chronic history of heart disease&#xD;
&#xD;
         16. Any condition that would, in the Investigator's judgment, interfere with full&#xD;
             participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mats Remberger, Professor</last_name>
    <role>Study Director</role>
    <affiliation>KFUE, Uppsala University Hospital, Uppsala, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulla Olsson-StrÃ¶mberg, AssProfessor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep of Hematology, Uppsala University Hospital, Uppsala, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mats Remberger, Professor</last_name>
    <phone>+46-701302575</phone>
    <email>mats.remberger@akademiska.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ulla Olsson-StrÃ¶mberg, AssProfessor</last_name>
    <phone>+46-709522667</phone>
    <email>ulla.olsson.stromberg@akademiska.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Copenhagen Univerity Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2300</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Niels Smedgaard-Andersen, AssProf</last_name>
      <email>niels.smedgaard.andersen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>NO-0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tobias Gedde-Dahl, Professor</last_name>
      <email>tgeddeda@ous-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gothenburg University Hospital</name>
      <address>
        <city>GÃ¶teborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan-Erik Johansson, AssProf</last_name>
      <email>jan-erik.j.johansson@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stig Lenhoff, AssProf</last_name>
      <email>stig.lenhoff@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Mielke, Professor</last_name>
      <email>stephan.mielke@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulla Olsson-StrÃ¶mberg, AssProf</last_name>
      <email>ulla.olsson.stromberg@akademiska.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <results_reference>
    <citation>Ringden O, Baygan A, Remberger M, Gustafsson B, Winiarski J, Khoein B, Moll G, Klingspor L, Westgren M, Sadeghi B. Placenta-Derived Decidua Stromal Cells for Treatment of Severe Acute Graft-Versus-Host Disease. Stem Cells Transl Med. 2018 Apr;7(4):325-331. doi: 10.1002/sctm.17-0167. Epub 2018 Mar 13.</citation>
    <PMID>29533533</PMID>
  </results_reference>
  <results_reference>
    <citation>Sadeghi B, Remberger M, Gustafsson B, Winiarski J, Moretti G, Khoein B, Klingspor L, Westgren M, Mattsson J, RingdÃ©n O. Long-Term Follow-Up of a Pilot Study Using Placenta-Derived Decidua Stromal Cells for Severe Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2019 Oct;25(10):1965-1969. doi: 10.1016/j.bbmt.2019.05.034. Epub 2019 Jun 4.</citation>
    <PMID>31173898</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 27, 2019</study_first_submitted>
  <study_first_submitted_qc>October 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University Hospital</investigator_affiliation>
    <investigator_full_name>Mats Remberger</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>DSC</keyword>
  <keyword>BAT</keyword>
  <keyword>GVHD</keyword>
  <keyword>HSCT</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Vedolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

